Investing.com - MEDIFAST (NYSE: MED) reported first quarter EPS of $3.67, $0.41 better than the analyst estimate of $3.26. Revenue for the quarter came in at $349M versus the consensus estimate of $374.3M.
Guidance
MEDIFAST sees Q2 2023 EPS of $1.32-$1.44 versus the analyst consensus of $2.82.
MEDIFAST sees Q2 2023 revenue of $250.00M-$270.00M versus the analyst consensus of $313.16M.
MEDIFAST's stock price closed at $90.50. It is down -21.30% in the last 3 months and down -48.15% in the last 12 months.
MEDIFAST saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See MEDIFAST's stock price’s past reactions to earnings here.
According to InvestingPro, MEDIFAST's Financial Health score is "great performance".
Check out MEDIFAST's recent earnings performance, and MEDIFAST's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar